Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study

Sara Y. Tartof(Kaiser Permanente), John M. McLaughlin(Pfizer (United States)), Srinivas Rao Valluri(Pfizer (United States)), Fagen Xie(Kaiser Permanente), Bradley K. Ackerson, Jeff Slezak(Kaiser Permanente), Luis Jódar(Pfizer (United States)), Vennis Hong(Kaiser Permanente), Laura Puzniak(Pfizer (United States))
The Lancet Respiratory Medicine
April 22, 2022
10.1016/s2213-2600(22)00101-1
Cited by 152

Related Papers

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
|The Lancet|2021|1.7k
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
|The Lancet|2021|1.3k
A Multicenter Study of ICU Telemedicine Reengineering of Adult Critical Care
|CHEST Journal|2014|219
Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis
|Open Forum Infectious Diseases|2022|212
Effect on Survival of Longer Intervals Between Confirmed Diagnosis and Treatment Initiation Among Low-Income Women With Breast Cancer
|Journal of Clinical Oncology|2012|211